MedTrace Logo

Sugammadex and Brain Waves

NCT01142648 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-06-11

No results posted yet for this study

Summary

According to our experience, electroencephalogram-based indices of anaesthetic state show elevated numbers after administration of sugammadex (new reversal of neuromuscular blockade). This can be due to altered anaesthetic state, or some kind of artefact. In this study, the phenomenon is evaluated in detail.

Conditions

  • Anaesthesia

Interventions

DRUG

Sugammadex

Sugammadex 200 mg iv, single dose, bolus.

DRUG

Neostigmine and glycopyrrolate

Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline

Sponsors & Collaborators

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Arvi Yli-Hankala, MD · Tampere University Hospital

  • Arvi Yli-Hankala, MD · Tampere University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01142648 on ClinicalTrials.gov